MCID: PLC011
MIFTS: 63

Pilocytic Astrocytoma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Pilocytic Astrocytoma

MalaCards integrated aliases for Pilocytic Astrocytoma:

Name: Pilocytic Astrocytoma 12 49 55 28 51 14 69
Juvenile Pilocytic Astrocytoma 49 69
Grade I Astrocytic Tumor 12
Piloid Astrocytoma 12

Characteristics:

Orphanet epidemiological data:

55
pilocytic astrocytoma
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4851
MeSH 41 D001254
NCIt 46 C4047
Orphanet 55 ORPHA251612
UMLS via Orphanet 70 C0334583
ICD10 via Orphanet 33 C71.9
UMLS 69 C0334583

Summaries for Pilocytic Astrocytoma

NIH Rare Diseases : 49 Pilocytic astrocytoma is an often benign, slow-growing tumor of the brain or spinal cord. The tumor may be in the form of a cyst and usually does not spread to nearby tissues. Symptoms vary depending upon the size and location of the tumor. Most symptoms result from increased pressure on the brain and include headaches, nausea, vomiting, balance problems, and vision abnormalities. The underlying cause of a pilocytic astrocytoma is unknown. It most commonly occurs in children and young adults, and in people with neurofibromatosis type 1 (NF1), Li-Fraumeni syndrome, and tuberous sclerosis. This type of tumor can often be cured with surgery. Last updated: 8/9/2013

MalaCards based summary : Pilocytic Astrocytoma, also known as juvenile pilocytic astrocytoma, is related to childhood pilocytic astrocytoma and pilocytic astrocytoma of cerebellum, and has symptoms including headache An important gene associated with Pilocytic Astrocytoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and HIV Life Cycle. The drugs Fentanyl and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include the brain, brain and spinal cord, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An astrocytoma that is characterized by cells that look like fibers when viewed under a microscope and is located in the brain.

Wikipedia : 72 Pilocytic astrocytoma or juvenile pilocytic astrocytoma or cystic cerebellar astrocytoma (and its... more...

Related Diseases for Pilocytic Astrocytoma

Diseases in the Pilocytic Astrocytoma family:

Juvenile Pilocytic Astrocytoma

Diseases related to Pilocytic Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
# Related Disease Score Top Affiliating Genes
1 childhood pilocytic astrocytoma 34.5 KIAA1549 NF1 PBX3
2 pilocytic astrocytoma of cerebellum 34.4 BRAF IDH1 KIAA1549 NF1
3 juvenile pilocytic astrocytoma 34.4 CDKN2A GFAP NF1 TIMP3
4 neurofibromatosis, type iv, of riccardi 31.3 KRAS NF1 PTPN11
5 astrocytoma 31.2 CDKN2A FGFR1 GFAP IDH1 KIAA1549 KRAS
6 glioblastoma 31.1 BRAF CDKN2A FGFR1 IDH1
7 glioblastoma multiforme 30.8 BRAF CDKN2A GFAP IDH1
8 gliofibroma 30.8 GFAP NF1
9 pilomyxoid astrocytoma 30.7 GFAP KIAA1549 SYP
10 ganglioglioma 30.7 BRAF GFAP SYP
11 ependymoma 30.6 GFAP SYP TIMP3
12 dysembryoplastic neuroepithelial tumor 30.6 GFAP IDH1 SYP
13 anaplastic oligodendroglioma 30.5 CDKN2A IDH1
14 noonan syndrome 1 30.4 BRAF KRAS NF1 PTPN11 RAF1
15 oligodendroglioma 30.4 CDKN2A GFAP IDH1 OLIG2 SYP
16 encephalocraniocutaneous lipomatosis 30.4 FGFR1 KRAS
17 gliosarcoma 30.3 FGFR1 GFAP IDH1
18 tanycytic ependymoma 30.2 GFAP OLIG2 SYP
19 pleomorphic xanthoastrocytoma 30.2 BRAF GFAP IDH1 SYP
20 medulloblastoma 30.1 GFAP NTRK2 SYP TIMP3
21 adenocarcinoma 30.1 BRAF CDKN2A KRAS NTRK2 RAF1
22 obstructive hydrocephalus 29.9 GFAP NF1 SRGAP3 SYP
23 cerebellar astrocytoma 10.7 BRAF IDH1 KIAA1549
24 autosomal dominant café au lait spots 10.6 NF1 PTPN11
25 spitz nevus 10.6 BRAF CDKN2A
26 syringocystadenoma papilliferum 10.6 BRAF GFAP KRAS
27 noonan syndrome with multiple lentigines 10.6 BRAF PTPN11 RAF1
28 fibrillary astrocytoma 10.6 GFAP IDH1 KIAA1549
29 cellular schwannoma 10.6 CDKN2A NF1 SOX10
30 hypertelorism 10.6 BRAF PTPN11 RAF1
31 hyperplastic polyposis syndrome 10.6 BRAF KRAS
32 lentigines 10.6 BRAF PTPN11 RAF1
33 differentiated thyroid carcinoma 10.6 BRAF CDKN2A KRAS
34 cardiofaciocutaneous syndrome 1 10.6 BRAF KRAS PTPN11
35 neurilemmoma 10.6 GFAP NF1 SOX10
36 li-fraumeni syndrome 10.6 CDKN2A IDH1 NF1
37 leopard syndrome 10.5 BRAF NF1 PTPN11 RAF1
38 atypical neurofibroma 10.5 CDKN2A GFAP NF1 SOX10
39 neurofibromatosis-noonan syndrome 10.5 NF1 PTPN11
40 malignant peripheral nerve sheath tumor 10.5 CDKN2A NF1 SOX10
41 adult oligodendroglioma 10.5 FGFR1 IDH1 NF1
42 pulmonic stenosis 10.5 BRAF KRAS NF1 PTPN11 RAF1
43 tumor suppressor gene on chromosome 11 10.5 BRAF KRAS
44 juvenile myelomonocytic leukemia 10.4 BRAF KRAS NF1 PTPN11 RAF1
45 lung cancer susceptibility 3 10.4 BRAF CDKN2A ERBB3 KRAS RAF1
46 st. louis encephalitis 10.4 KRAS RAF1
47 desmoplastic infantile ganglioglioma 10.4 GFAP SYP
48 malignant glandular tumor of peripheral nerve sheath 10.4 NF1 SYP
49 leukemia, acute myeloid 10.4 CDKN2A IDH1 KRAS PBX3 PTPN11
50 rhabdoid meningioma 10.4 BRAF GFAP SYP

Graphical network of the top 20 diseases related to Pilocytic Astrocytoma:



Diseases related to Pilocytic Astrocytoma

Symptoms & Phenotypes for Pilocytic Astrocytoma

UMLS symptoms related to Pilocytic Astrocytoma:


headache

GenomeRNAi Phenotypes related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

25 (show top 50) (show all 53)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.99 KRAS BRAF
2 Decreased viability GR00106-A-0 10.99 KRAS ERBB3
3 Decreased viability GR00221-A-1 10.99 NF1 KRAS NTRK2 FGFR1 RAF1 CDKN2A
4 Decreased viability GR00221-A-2 10.99 NF1 KRAS NTRK2 FGFR1 RAF1 ERBB3
5 Decreased viability GR00221-A-3 10.99 CDKN2A
6 Decreased viability GR00221-A-4 10.99 NF1 NTRK2 BRAF ERBB3 CDKN2A
7 Decreased viability GR00231-A 10.99 RAF1
8 Decreased viability GR00301-A 10.99 KRAS RAF1 ERBB3 BRAF
9 Decreased viability GR00342-S-2 10.99 ERBB3
10 Decreased viability GR00342-S-3 10.99 ERBB3
11 Decreased viability GR00381-A-1 10.99 KRAS BRAF
12 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.3 FGFR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.3 BRAF
14 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.3 PTPN11
15 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.3 PTPN11
16 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.3 FGFR1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.3 FGFR1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.3 IDH1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.3 SRGAP3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.3 IDH1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.3 IDH1 PTPN11
22 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.3 IDH1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.3 PTPN11 BRAF
24 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.3 SRGAP3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.3 BRAF
26 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.3 FGFR1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.3 IDH1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.3 BRAF
29 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.3 PTPN11
30 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.3 FGFR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.3 PTPN11
32 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.3 BRAF
33 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.3 SRGAP3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.3 BRAF
35 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.3 SRGAP3
36 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.3 BRAF
37 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.3 BRAF
38 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.3 SRGAP3
39 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.3 PTPN11
40 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.3 IDH1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.3 SRGAP3 FGFR1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.3 FGFR1 IDH1 SRGAP3 PTPN11 BRAF
43 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.3 FGFR1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.3 PTPN11
45 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.3 FGFR1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.3 PTPN11
47 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.3 SRGAP3
48 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.3 FGFR1
49 Decreased viability in esophageal squamous lineage GR00235-A 10.02 GFAP KRAS IDH1 KIAA1549 SOX10 PTPN11
50 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.8 FGFR1 RAF1 NTRK2 ERBB3 BRAF

MGI Mouse Phenotypes related to Pilocytic Astrocytoma:

43 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.59 GFAP FGFR1 GTF2I NTRK2 NF1 KIAA1549
2 cellular MP:0005384 10.47 ERBB3 GFAP FGFR1 GTF2I NF1 KRAS
3 homeostasis/metabolism MP:0005376 10.47 IDH1 GFAP FGFR1 NTRK2 KIAA1549 NF1
4 growth/size/body region MP:0005378 10.46 IDH1 GFAP FGFR1 GTF2I NF1 KRAS
5 mortality/aging MP:0010768 10.43 IDH1 GFAP FGFR1 GTF2I NTRK2 NF1
6 cardiovascular system MP:0005385 10.42 GTF2I ERBB3 GFAP FGFR1 NF1 KRAS
7 endocrine/exocrine gland MP:0005379 10.38 FGFR1 GTF2I NF1 KRAS PBX3 NTRK2
8 nervous system MP:0003631 10.33 GFAP FGFR1 GTF2I NTRK2 NF1 KRAS
9 immune system MP:0005387 10.3 FGFR1 ERBB3 GFAP NF1 KRAS IDH1
10 digestive/alimentary MP:0005381 10.28 FGFR1 ERBB3 GFAP NF1 KRAS PTPN11
11 embryo MP:0005380 10.27 GTF2I FGFR1 ERBB3 KRAS NF1 PTPN11
12 integument MP:0010771 10.25 FGFR1 ERBB3 KRAS NF1 PTPN11 PBX3
13 muscle MP:0005369 10.2 ERBB3 GFAP FGFR1 NF1 KRAS OLIG2
14 craniofacial MP:0005382 10.19 GTF2I FGFR1 KRAS NF1 PTPN11 PBX3
15 adipose tissue MP:0005375 10.16 KIAA1549 PBX3 NTRK2 OLIG2 BRAF PTPN11
16 hearing/vestibular/ear MP:0005377 10.15 FGFR1 KRAS NF1 PTPN11 NTRK2 BRAF
17 liver/biliary system MP:0005370 10.1 NF1 KRAS NTRK2 CDKN2A BRAF RAF1
18 normal MP:0002873 10.1 ERBB3 GFAP FGFR1 GTF2I NF1 KRAS
19 neoplasm MP:0002006 10.09 ERBB3 NF1 KRAS OLIG2 PTPN11 CDKN2A
20 respiratory system MP:0005388 9.97 IDH1 NTRK2 NF1 KRAS PBX3 PTPN11
21 no phenotypic analysis MP:0003012 9.91 GTF2I FGFR1 KRAS OLIG2 CDKN2A RAF1
22 pigmentation MP:0001186 9.86 ERBB3 NF1 KRAS PTPN11 BRAF CDKN2A
23 skeleton MP:0005390 9.7 FGFR1 KRAS IDH1 NF1 PTPN11 PBX3
24 vision/eye MP:0005391 9.36 FGFR1 GFAP NF1 KRAS NTRK2 OLIG2

Drugs & Therapeutics for Pilocytic Astrocytoma

Drugs for Pilocytic Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
3
Vincristine Approved, Investigational Phase 2, Phase 3,Phase 1 2068-78-2, 57-22-7 5978
4
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
5
Procarbazine Approved, Investigational Phase 2, Phase 3 671-16-9 4915
6
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
7
Cyproheptadine Approved Phase 3 129-03-3 2913
8
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
9
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
10 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
11 Alkylating Agents Phase 2, Phase 3,Phase 1
12 Dermatologic Agents Phase 3,Phase 2,Phase 1
13 Adjuvants, Anesthesia Phase 3
14 Analgesics Phase 3
15 Analgesics, Opioid Phase 3
16 Anesthetics Phase 3
17 Anesthetics, General Phase 3
18 Anesthetics, Intravenous Phase 3
19 Central Nervous System Depressants Phase 3
20 Liver Extracts Phase 3,Phase 2,Phase 1
21 Narcotics Phase 3
22 Peripheral Nervous System Agents Phase 3
23 Cholinergic Agents Phase 3,Phase 2
24 Cholinesterase Inhibitors Phase 3,Phase 2
25 Neurotransmitter Agents Phase 3,Phase 2
26 Nootropic Agents Phase 3,Phase 2
27 Antimitotic Agents Phase 2, Phase 3,Phase 1
28 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
29 Gastrointestinal Agents Phase 3,Phase 1
30 Central Nervous System Stimulants Phase 3,Phase 2
31 Dopamine Agents Phase 3
32 Anti-Allergic Agents Phase 3
33 Antipruritics Phase 3
34 Histamine Antagonists Phase 3
35 Histamine H1 Antagonists Phase 3
36
Histamine Phosphate Phase 3 51-74-1 65513
37
Serotonin Phase 3 50-67-9 5202
38 Serotonin Agents Phase 3
39 Serotonin Antagonists Phase 3
40 Dexmethylphenidate Hydrochloride Phase 3
41 Dopamine Uptake Inhibitors Phase 3
42 Neurotransmitter Uptake Inhibitors Phase 3
43 Cola Nutraceutical Phase 3,Phase 1
44
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
45
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
46
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
47
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
48
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
49
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 46835353 6436030 5284616
50
Carmustine Approved, Investigational Phase 2,Phase 1 154-93-8 2578

Interventional clinical trials:

(show top 50) (show all 66)

# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
3 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
4 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
6 Temozolomide in Treating Patients With Low-Grade Glioma Completed NCT00313729 Phase 2 temozolomide
7 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
8 Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
9 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
10 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
11 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
12 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
13 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
14 Imatinib Mesylate in Treating Patients With Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
15 Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors Completed NCT00025675 Phase 2 gefitinib
16 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
17 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
18 Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
19 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
20 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
21 Antineoplaston Therapy in Treating Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
22 Phase II Pegylated Interferon Recruiting NCT02343224 Phase 2 Pegylated interferon alpha-2b
23 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
24 Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Recruiting NCT01089101 Phase 1, Phase 2 Selumetinib
25 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Active, not recruiting NCT01553149 Phase 2 Lenalidomide
26 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
27 Bevacizumab in Recurrent Grade II and III Glioma Active, not recruiting NCT01164189 Phase 2 Temozolomide
28 Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting NCT00553150 Phase 1, Phase 2 everolimus;temozolomide
29 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
30 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
31 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
32 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
33 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
34 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
35 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
36 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
37 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
38 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
39 Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00509431 Phase 1 Erlotinib + Sirolimus
40 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
41 BCX-1777 in Treating Patients With Refractory Cancer Completed NCT00073944 Phase 1 forodesine hydrochloride
42 Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin
43 Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors Completed NCT00003484 Phase 1 carmustine;irinotecan hydrochloride
44 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
45 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
46 Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas Completed NCT00019019 Phase 1 carboxyamidotriazole;paclitaxel
47 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
48 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
49 Cognitive Biomarkers in Pediatric Brain Tumor Patients Recruiting NCT02914067 Phase 1
50 Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors Recruiting NCT02372409 Phase 1 Doxorubicin;Etoposide

Search NIH Clinical Center for Pilocytic Astrocytoma

Genetic Tests for Pilocytic Astrocytoma

Genetic tests related to Pilocytic Astrocytoma:

# Genetic test Affiliating Genes
1 Pilocytic Astrocytoma 28

Anatomical Context for Pilocytic Astrocytoma

The Foundational Model of Anatomy Ontology organs/tissues related to Pilocytic Astrocytoma:

18
The Brain

MalaCards organs/tissues related to Pilocytic Astrocytoma:

38
Brain, Spinal Cord, Cerebellum, Liver, Bone, Pineal, Kidney

Publications for Pilocytic Astrocytoma

Articles related to Pilocytic Astrocytoma:

(show top 50) (show all 418)
# Title Authors Year
1
Delayed leptomeningeal metastasis of an adult anaplastic pilocytic astrocytoma. ( 29330645 )
2018
2
Pilocytic astrocytoma with leptomeningeal spread in a patient with incontinentia pigmenti presenting with unilateral nystagmus. ( 29171168 )
2018
3
Management and survival of adult patients with pilocytic astrocytoma in the National Cancer Database. ( 29427814 )
2018
4
Mitogen-activated protein kinase in gliosis and pilocytic astrocytoma. ( 29168690 )
2018
5
Supratentorial extension of large cerebellar pilocytic astrocytoma in adult. ( 29446978 )
2018
6
Long-term outcomes of primarily metastatic juvenile pilocytic astrocytoma in children. ( 29125440 )
2018
7
Long-Term Remission of Recurrent Brainstem Pilocytic Astrocytoma with Neuraxis Dissemination Using Recombinant Human Endostatin After Failure of Vincristine and Carboplatin. ( 29203315 )
2018
8
Adult Pilocytic Astrocytoma: An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence. ( 29180079 )
2018
9
Longitudinal mutational analysis of a cerebellar pilocytic astrocytoma recurring as a ganglioglioma. ( 27718322 )
2017
10
Pilocytic astrocytoma: A rare presentation as intraventricular tumor. ( 28680735 )
2017
11
Cerebellar pilocytic astrocytoma in childhood: Investigating the long-term impact of surgery on cognitive performance and functional outcome. ( 28968151 )
2017
12
Midbrain Gliofibroma Presenting in Adulthood following "Cure" of a Childhood Intraventricular Pilocytic Astrocytoma. ( 28245445 )
2017
13
Recurrent Optic Nerve Pilocytic Astrocytoma: A Rare Case. ( 28658822 )
2017
14
Evaluation of outcomes after stereotactic radiosurgery for pilocytic astrocytoma. ( 28567590 )
2017
15
Correction: A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. ( 28880959 )
2017
16
Pilocytic astrocytoma of the cerebellopontine angle mimicking vestibular schwannoma: report of a rare entity. ( 29278012 )
2017
17
Hydrocephalus associated with spinal intramedullary pilocytic astrocytoma. ( 28484535 )
2017
18
Brainstem pilocytic astrocytoma with H3 K27M mutation: case report. ( 28960151 )
2017
19
Isolated Trochlear Palsy Due to Pilocytic Astrocytoma Involving the Pineal Gland. ( 28831788 )
2017
20
Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy. ( 28137267 )
2017
21
A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. ( 28448514 )
2017
22
Exophytic bulbar pilocytic astrocytoma and post-operative cerebral salt wasting syndrome. ( 28478813 )
2017
23
A novel GIT2-BRAF fusion in pilocytic astrocytoma. ( 29141672 )
2017
24
Cathepsin L silencing increases As2O3 toxicity in malignantly transformed pilocytic astrocytoma MPA58 cells by activating caspases 3/7. ( 28412241 )
2017
25
Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient. ( 29061673 )
2017
26
Supratentorial Pilocytic Astrocytoma Mimicking Convexity Meningioma with Early Anaplastic Transformation: A Case Report. ( 29188212 )
2017
27
Resection of a Pediatric Thalamic Juvenile Pilocytic Astrocytoma with Whole Brain Tractography. ( 29234572 )
2017
28
Methylation profiling of paediatric pilocytic astrocytoma reveals variants specifically associated with tumour location and predictive of recurrence. ( 28388012 )
2017
29
A Case of Leptomeningeal Dissemination of Pilocytic Astrocytoma in a Child. ( 28446265 )
2017
30
Adult pilocytic astrocytoma of conus medullaris: clinical considerations and review of the literature. ( 28425761 )
2017
31
Pilocytic astrocytoma mimicking cavernous angioma: Imaging features and histological characteristics. ( 28919136 )
2017
32
Pilocytic Astrocytoma Enlargement Following Irradiation: Relapse or Pseudoprogression? ( 28367384 )
2017
33
Tanycytic ependymoma vs pilocytic astrocytoma? Pitfalls in diagnosis. ( 27773093 )
2016
34
Adult anaplastic pilocytic astrocytoma - a diagnostic challenge? A case series and literature review. ( 27341279 )
2016
35
Malignant progression of a histone H3.3 K27M-mutated spinal pilocytic astrocytoma in an adult. ( 27900936 )
2016
36
Spontaneous aneurysmal subarachnoid haemorrhage in a child with multiply recurrent posterior fossa juvenile pilocytic astrocytoma. ( 27927709 )
2016
37
Spontaneous complete regression of hypothalamic pilocytic astrocytoma after partial resection in a child, complicated with Stevens-Johnson syndrome: a case report and literature review. ( 26662551 )
2016
38
Postoperative surveillance of pediatric cerebellar pilocytic astrocytoma. ( 27502785 )
2016
39
Cranial pilocytic astrocytoma with spinal drop metastasis in an adult: case report and literature review. ( 27535634 )
2016
40
A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma. ( 27810072 )
2016
41
Infratentorial ganglioglioma mimicking pilocytic astrocytoma. ( 27936528 )
2016
42
miR-15a and miR-24-1 as putative prognostic microRNA signatures for pediatric pilocytic astrocytomas and ependymomas. ( 26813564 )
2016
43
Pilocytic astrocytoma. ( 27033282 )
2016
44
Heterogeneity of histopathological presentation of pilocytic astrocytoma - diagnostic pitfalls. A review. ( 27764513 )
2016
45
Report of effective trametinib therapy in 2 children with progressive hypothalamic optic pathway pilocytic astrocytoma: documentation of volumetric response. ( 28009226 )
2016
46
Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma. ( 27608415 )
2016
47
Retraction: Screening genes crucial for pediatric pilocytic astrocytoma using weighted gene coexpression network analysis combined with methylation data analysis. ( 26685762 )
2016
48
Pineal region pilocytic astrocytoma; an unusual site with variable radiological, clinical, and histological features: A report of two cases. ( 27365971 )
2016
49
TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma. ( 27374106 )
2016
50
Suprasellar pilocytic astrocytoma in an adult with hemorrhage and leptomeningeal dissemination: case report and review of literature. ( 27920871 )
2016

Variations for Pilocytic Astrocytoma

ClinVar genetic disease variations for Pilocytic Astrocytoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh37 Chromosome 12, 25398282: 25398282

Copy number variations for Pilocytic Astrocytoma from CNVD:

7 (show all 22)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 38161 10 1 3000000 Gain DIP2C Pilocytic astrocytoma
2 40599 10 130600000 135534747 Loss DRD1IP Pilocytic astrocytoma
3 64537 12 129300000 133851895 Loss BCL7A Pilocytic astrocytoma
4 84233 14 24600000 33300000 Loss FOXG1B Pilocytic astrocytoma
5 97079 15 98500000 102531392 Loss LASS3 Pilocytic astrocytoma
6 112680 17 40811265 40819024 Loss TUBG2 Pilocytic astrocytoma
7 112684 17 40834631 40852011 Loss CNTNAP1 Pilocytic astrocytoma
8 220399 7 138200000 143100000 Amplification Pilocytic astrocytoma
9 227901 7 72200000 77500000 Loss BCL7B Pilocytic astrocytoma
10 230764 8 1 2200000 Loss Pilocytic astrocytoma
11 234563 8 136400000 146364022 Gain COL22A1 Pilocytic astrocytoma
12 234873 8 139900000 146364022 Gain CYHR1 Pilocytic astrocytoma
13 234878 8 139900000 146364022 Gain FOXH1 Pilocytic astrocytoma
14 234881 8 139900000 146364022 Gain GPT Pilocytic astrocytoma
15 234884 8 139900000 146364022 Gain KIFC2 Pilocytic astrocytoma
16 234886 8 139900000 146364022 Gain LRRC14 Pilocytic astrocytoma
17 234888 8 139900000 146364022 Gain LRRC24 Pilocytic astrocytoma
18 234890 8 139900000 146364022 Gain MFSD3 Pilocytic astrocytoma
19 234893 8 139900000 146364022 Gain PPP1R16A Pilocytic astrocytoma
20 234897 8 139900000 146364022 Gain RECQL4 Pilocytic astrocytoma
21 244900 9 1 2200000 Loss ANKRD15 Pilocytic astrocytoma
22 256191 9 9000000 28000000 Loss SH3GL2 Pilocytic astrocytoma

Expression for Pilocytic Astrocytoma

Search GEO for disease gene expression data for Pilocytic Astrocytoma.

Pathways for Pilocytic Astrocytoma

Pathways related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 BRAF CDKN2A ERBB3 FGFR1 KRAS NF1
2
Show member pathways
13.71 BRAF ERBB3 FGFR1 IDH1 KIAA1549 KRAS
3
Show member pathways
13.53 BRAF ERBB3 FGFR1 KRAS NTRK2 PTPN11
4
Show member pathways
13.49 BRAF ERBB3 FGFR1 KRAS NF1 PTPN11
5
Show member pathways
13.35 BRAF ERBB3 FGFR1 KRAS NF1 PTPN11
6
Show member pathways
13.26 BRAF ERBB3 FGFR1 KRAS NTRK2 RAF1
7
Show member pathways
13.05 BRAF FGFR1 KRAS NTRK2 RAF1 TIMP3
8
Show member pathways
13.02 BRAF CDKN2A ERBB3 FGFR1 KRAS NF1
9 12.82 BRAF CDKN2A FGFR1 KRAS RAF1
10
Show member pathways
12.75 BRAF CDKN2A FGFR1 KRAS RAF1
11 12.72 BRAF FGFR1 KRAS NF1 NTRK2 RAF1
12
Show member pathways
12.64 BRAF ERBB3 KRAS NTRK2 PTPN11 RAF1
13
Show member pathways
12.51 BRAF FGFR1 KRAS NF1 NTRK2 PTPN11
14 12.5 CDKN2A ERBB3 KRAS RAF1 TIMP3
15
Show member pathways
12.48 BRAF ERBB3 FGFR1 KRAS RAF1
16
Show member pathways
12.47 BRAF ERBB3 KRAS RAF1
17
Show member pathways
12.45 BRAF ERBB3 KRAS PTPN11 RAF1
18
Show member pathways
12.42 ERBB3 FGFR1 KRAS NTRK2
19
Show member pathways
12.36 BRAF KRAS NF1 PTPN11 RAF1
20
Show member pathways
12.33 BRAF GTF2I KRAS PTPN11 RAF1
21
Show member pathways
12.28 BRAF KRAS NF1 RAF1
22
Show member pathways
12.25 BRAF FGFR1 KRAS PTPN11
23
Show member pathways
12.21 FGFR1 KRAS RAF1 TIMP3
24
Show member pathways
12.2 BRAF KRAS PTPN11 RAF1 TIMP3
25 12.19 KRAS PTPN11 RAF1 SRGAP3
26 12.16 BRAF KRAS PTPN11 RAF1
27
Show member pathways
12.12 BRAF ERBB3 FGFR1 KRAS NTRK2 RAF1
28
Show member pathways
12.06 BRAF CDKN2A KRAS PTPN11 RAF1
29
Show member pathways
11.97 BRAF KIAA1549 KRAS NF1 RAF1
30 11.88 FGFR1 GFAP OLIG2 SOX10
31 11.86 BRAF KRAS RAF1
32 11.76 BRAF KRAS RAF1
33
Show member pathways
11.74 BRAF FGFR1 KRAS RAF1
34 11.71 BRAF KRAS NF1 PTPN11 RAF1
35 11.67 BRAF CDKN2A KRAS RAF1
36
Show member pathways
11.65 BRAF KRAS RAF1
37 11.61 BRAF KRAS RAF1
38 11.61 FGFR1 IDH1 KRAS RAF1
39 11.6 BRAF CDKN2A KRAS NF1 RAF1
40 11.5 KRAS NF1 RAF1
41 11.47 BRAF ERBB3 FGFR1 KRAS PTPN11 RAF1
42 11.46 ERBB3 FGFR1 NTRK2
43 11.32 BRAF KRAS NTRK2
44 11.29 BRAF FGFR1 KRAS RAF1
45 11.26 BRAF ERBB3 FGFR1 KRAS NTRK2 RAF1
46 11.25 FGFR1 GFAP OLIG2 SOX10 SYP
47 11.2 BRAF KRAS RAF1
48 11.01 ERBB3 FGFR1 GFAP NTRK2 RAF1 TIMP3
49 10.85 NTRK2 RAF1

GO Terms for Pilocytic Astrocytoma

Biological processes related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.95 BRAF CDKN2A ERBB3 FGFR1 NTRK2 RAF1
2 brain development GO:0007420 9.88 APOD FGFR1 NF1 PTPN11
3 regulation of cell proliferation GO:0042127 9.86 BRAF ERBB3 FGFR1 NF1
4 heart development GO:0007507 9.85 ERBB3 NF1 PTPN11 RAF1
5 wound healing GO:0042060 9.77 ERBB3 NF1 RAF1
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.74 BRAF NTRK2 RAF1
7 Ras protein signal transduction GO:0007265 9.71 CDKN2A KRAS NF1
8 negative regulation of neuron apoptotic process GO:0043524 9.71 BRAF ERBB3 KRAS NTRK2
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.7 ERBB3 FGFR1 NTRK2
10 negative regulation of signal transduction GO:0009968 9.69 BRAF ERBB3 RAF1
11 visual learning GO:0008542 9.63 BRAF KRAS NF1
12 regulation of protein complex assembly GO:0043254 9.61 GFAP PTPN11
13 neurotrophin TRK receptor signaling pathway GO:0048011 9.61 PTPN11 RAF1
14 long-term synaptic potentiation GO:0060291 9.61 BRAF GFAP NTRK2
15 positive regulation of cellular senescence GO:2000774 9.6 CDKN2A KRAS
16 regulation of synaptic transmission, GABAergic GO:0032228 9.58 KRAS NF1
17 oligodendrocyte differentiation GO:0048709 9.54 NTRK2 OLIG2 SOX10
18 Bergmann glial cell differentiation GO:0060020 9.49 GFAP PTPN11
19 peripheral nervous system development GO:0007422 9.43 ERBB3 NF1 SOX10
20 positive regulation of gene expression GO:0010628 9.43 BRAF CDKN2A ERBB3 KRAS NTRK2 SOX10
21 regulation of long-term neuronal synaptic plasticity GO:0048169 9.33 KRAS NF1 SYP
22 forebrain astrocyte development GO:0021897 9.32 KRAS NF1
23 MAPK cascade GO:0000165 9.1 BRAF ERBB3 FGFR1 KRAS NF1 RAF1

Molecular functions related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.77 BRAF ERBB3 FGFR1 NTRK2 RAF1
2 kinase activity GO:0016301 9.73 BRAF CDKN2A ERBB3 FGFR1 NTRK2 RAF1
3 nucleotide binding GO:0000166 9.55 BRAF ERBB3 FGFR1 KRAS RAF1
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 ERBB3 FGFR1 PTPN11
5 identical protein binding GO:0042802 9.23 BRAF ERBB3 FGFR1 GFAP IDH1 RAF1
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 ERBB3 FGFR1 NTRK2

Sources for Pilocytic Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....